Provided by Tiger Trade Technology Pte. Ltd.

FUSEN PHARM

1.250
0.000
Volume:- -
Turnover:- -
Market Cap:923.75M
PE:-68.51
High:1.250
Open:1.250
Low:1.250
Close:1.250
52wk High:1.750
52wk Low:0.235
Shares:739.00M
HK Float Shares:739.00M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.018
ROE:-3.25%
ROA:-0.46%
PB:2.24
PE(LYR):-68.52
PS:2.94

Loading ...

Fusen Pharmaceutical Co Ltd - Measartan Potassium Tablets Approved for Marketing

THOMSON REUTERS
·
Nov 14, 2025

Further weakness as Fusen Pharmaceutical (HKG:1652) drops 12% this week, taking five-year losses to 85%

Simply Wall St.
·
Nov 09, 2025

Fusen Pharmaceutical (01652) Reports October 2025 Monthly Securities Movements

Bulletin Express
·
Nov 03, 2025

HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program

Stock News
·
Oct 31, 2025

FUSEN PHARM (01652): "Enzalutamide Soft Capsule" Approved for Market Launch

Stock News
·
Oct 30, 2025

Fusen Pharmaceutical Wins Approval for Enzalutamide Soft Capsules in China

Reuters
·
Oct 30, 2025

BRIEF-Fusen Pharmaceutical Says Enzalutamide Soft Capsules Approved For Marketing by NMPA

Reuters
·
Oct 30, 2025

Fusen Pharmaceutical Co Ltd - Enzalutamide Soft Capsules Approved for Marketing

THOMSON REUTERS
·
Oct 30, 2025

Fusen Pharmaceutical - Approval From China's National Medical Products Administration

THOMSON REUTERS
·
Oct 30, 2025

Fusen Pharmaceutical (1652) Announces Selection in Eleventh Batch of National Centralised Medicines Procurement

Bulletin Express
·
Oct 30, 2025

FUSEN PHARM (01652): Metformin Empagliflozin Tablets (I) Shortlisted in China's 11th National Drug Centralized Procurement Bidding

Stock News
·
Oct 30, 2025

Fusen Pharmaceutical (1652) Announces Further Details on Disposal of Henan Fusen Energy Conservation Unit

Bulletin Express
·
Oct 27, 2025